A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs ENT 01 (Primary)
- Indications Constipation; Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms KARMET
- Sponsors Enterin
- 13 Nov 2019 Planned number of patients changed from 72 to 152.
- 13 Nov 2019 Status changed to recruiting.
- 13 Nov 2019 Planned End Date changed from 1 Nov 2019 to 1 Oct 2020.